SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (6552)4/17/2015 11:43:05 AM
From: Land Shark  Respond to of 7424
 
TROV up 24%

10:30 am TrovaGene announces that clinical data presented at the 2015 European Lung Cancer Conference demonstrate that its urine-based Precision Cancer Monitoring platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients ( TROV)



To: Jibacoa who wrote (6552)4/20/2015 6:55:47 PM
From: Jibacoa  Read Replies (3) | Respond to of 7424
 
NVGN was up 20.97% on volume >2x its ADV and has continued to do well AHs.<g>
It reported good results on its Cantrixil on ovarian Ca, on experiments been carried out at Yale's Labs.
finance.yahoo.com

The stock continues on its recent up-move.
The next resistance to watch is its Feb2014 H at 10.49 <g>
bigcharts.marketwatch.com

Bernard